ABA 2025 Antitrust Spring Meeting

The Current Status of FTC’s Orange Book Listings Challenge: A Mixed Bag

United States: Pharmaceutical Antitrust 2025

ABA 2024 Antitrust Spring Meeting

Federal Trade Commission Likely to Expand Labor Enforcement to Worker-Misclassification Issues

Uncertainty Remains More Than One Year After the FTC Announces New “Unfair Methods of Competition” Policy

United States: Pharmaceutical Antitrust 2024

Customer Outreach In Merger Reviews Checklist

Four Takeaways From The FTC’s Unprecedented Crackdown On Noncompete Agreements

United States: Pharmaceutical Antitrust 2023

Federal District Court holds that California's anti reverse payment law is enforceable, but only against settlements "negotiated, completed, or entered" in California

United States: Pharmaceutical Antitrust 2022

How Cos. Can Weather Growing DOJ Labor Antitrust Scrutiny

China Increases Penalties For Private Sector Bribery

Misguided Sensipar Ruling Threatens Patent Settlements

FTC Publishes Annual MMA Report—Continues to Scrutinize Pharma Patent Settlements

United States: Pharmaceutical Antitrust 2021

What’s Coming Next? Understanding the Next Big Areas in the Pharmaceutical Antitrust Wars